“The second patent application for our novel drug candidates incorporates new side-chain restricted analog designs - working from the progress of our first application - and broadens the strength of our patent estate,” said
Family 4 compounds are DMT and 5-MeO-DMT inspired drug candidates that offer a broad range of pharmacological diversity suitable for in-clinic settings. The Company has run a battery of specialized in-vitro and in-vivo tests on its patent-pending novel compounds to select the optimal psychedelic drug candidates for progressing towards human clinical trials.
To watch a video of Mindset’s CEO discuss the announcement in greater detail, please visit: https://youtu.be/EHnoPL-x3Ck
For more information, please contact:
Investor Contact:
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788
Company Contact:
Email: jlanthier@mindsetpharma.com
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094
About
For further information on Mindset, please visit our website at www.mindsetpharma.com.
Forward-Looking Information
This news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form for the financial year ended
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Source:
2021 GlobeNewswire, Inc., source